PD-1/PD-L1抑制剂联合治疗胰腺癌的研究进展

Progression of PD-1/PD-L1 inhibitor combination therapy in pancreatic cancer

程序性死亡蛋白1(PD-1)和程序性死亡蛋白配体1(PD-L1)是维持免疫稳态的重要蛋白, 也是肿瘤免疫逃逸的关键一环。PD-1/PD-L1抑制剂在许多癌症免疫治疗中取得了显著疗效, 但在胰腺癌治疗中效果有限, 单药治疗效果欠佳。有研究探索了PD-1/PD-L1抑制剂联合治疗效果, 如联合化疗、放疗、分子靶向治疗等, 从而提高PD-1/PD-L1抑制剂治疗疗效。本文总结了PD-1/PD-L1抑制剂联合治疗方案治疗胰腺癌的进展。

Programmed death protein 1(PD-1)and programmed death protein ligand-1(PD-L1)play pivotal roles in maintaining immune homeostasis and a crucial link in tumour immune evasion.PD-1/PD-L1 inhibitors have achieved significant efficacy in many cancer immunotherapy,but the effect in the treatment of pancreatic cancer is limited,and the effect of monotherapy is suboptimal.The combined therapeatic effect of PD-1/PD-L1 and chemotherapy,radiotherapy,and molecular targeted therapy were explored.This article summarises the advancements in PD-1/PD-L1 inhibitor combination therapy in the treatment of pancreatic cancer.